June 3, 2019 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal

Thermo Fisher Scientific's Oncomine Dx Target Test Receives Reimbursement Coverage in Japan

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives Reimbursement Coverage in Japan CARLSBAD, Calif., June 3, 2019 /PRNewswire/ — Thermo Fisher Scientific today announced that its Oncomine Dx Target Test CDx System has received reimbursement coverage from Japan’s Ministry of Health, Labour and Welfare and is now commercially available in that country. The next-generation sequencing (NGS)-based... Read more

June 3, 2019 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Announces Collaboration to Revolutionize Profiling of Large Plasma Sample Cohorts in Protein-based Clinical Research Studies

Thermo Fisher Scientific Announces Collaboration to Revolutionize Profiling of Large Plasma Sample Cohorts in Protein-based Clinical Research Studies ATLANTA, June 3, 2019 /PRNewswire/ — ASMS 2019 – Thermo Fisher Scientific, the world leader in serving science, and Evosep, a leading provider of sample preparation technologies for protein-based clinical research, have entered into a collaboration to develop... Read more

June 3, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships Mass Spectrometry

Thermo Fisher Scientific Renews Collaboration to Advance Plasma Quantitation Methods in Proteomics

Thermo Fisher Scientific Renews Collaboration to Advance Plasma Quantitation Methods in Proteomics Thermo Fisher and Biognosys to develop industry-leading mass spectrometry-based workflows for the efficient analysis of proteins in complex biological matrices ATLANTA, June 3, 2019 /PRNewswire/ — ASMS 2019 — Thermo Fisher Scientific, the world leader in serving science, and Biognosys, a leading developer of next-generation... Read more

June 3, 2019 Clinical Research/Diagn. PR/Corporate

Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Basel, 03 June 2019 Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Roche data from 17 breast cancer abstracts presented at this year’s meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative breast cancer at the second... Read more

May 31, 2019 Clinical Research/Diagn. Product Launch

Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care

Basel, 31 May 2019 Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of... Read more

May 30, 2019 Clinical Research/Diagn. M&A, Partnerships

NanoString Partners with Multiple Leading Contract Research Organizations to Provide Standardized PanCancer IO 360 Data Analysis Reports

Program Extends Ability of CAP CLIA Labs to Develop a Tumor Inflammation Signature Assay to Support Translational Research by Biopharmaceutical Companies SEATTLE, May 30, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced commercial partnerships with three Contract Research Organizations (CROs), including Covance, NeoGenomics Laboratories,... Read more

May 29, 2019 Clinical Research/Diagn.

Quanterix Expands Headquarters to New, State-of-the-art Facility in Billerica, Mass. As Demand Continues to Grow for Its Disruptive Simoa Platforms

MAY 29, 2019 World-class facility will offer the Company nearly three times the space for disruptive biomarker technology innovation and to accommodate growing pharma services business Billerica, Mass. – May 29, 2019 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters... Read more

May 28, 2019 Clinical Research/Diagn. Product Launch

Roche launches first in vitro diagnostic IHC test to detect ROS1 protein in cancers

VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody IHC staining of lung adenocarcinoma tissue Roche’s VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market The biomarker may provide a cost-effective and efficient means to initially identify elevated ROS1 protein expression in cancer ROS1-positive cancer... Read more

May 24, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Product Launch

QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer

Germantown, Maryland, and Hilden, Germany, May 24, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the immediate launch of its therascreen® PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY (alpelisib), a... Read more

May 21, 2019 Clinical Research/Diagn. PR/Corporate

QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

Hilden, Germany and Germantown, Maryland, May 21, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the Joint United Nations Programme on HIV/AIDS... Read more